Crossmark

In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat,

Crossref DOI link: https://doi.org/10.1186/s12876-025-03800-7

Published Online: 2025-03-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schwartz, Orna

Azrad, Maya

Peretz, Avi
License Information

Text and Data Mining valid from 2025-03-31

Version of Record valid from 2025-03-31
More Information

Article History

Received: 13 January 2025

Accepted: 18 March 2025

First Online: 31 March 2025

Declarations

:

: The study adhered to the Declaration of Helsinki. Tzafon Medical Center, Poriya and W. Hirsch Regional Microbiology Laboratory Clalit Health Services, Haifa, Center - Edith Wolfson Medical Center, Holon, and South - Soroka University Medical Center, Be’er Sheva. The local Ethics (Helsinki) Committee of Tzafon Medical Center, W. Hirsch Regional Microbiology Laboratory Clalit Health Services and Soroka University Medical Center approved the study (approval numbers-POR-0085-15, WOMC-0115-20, SOR-0307-20, respectively). The need for informed consent was waived by all three mentioned committees. All experiments were performed in accordance with relevant guidelines and regulations.

: Not applicable.

: The authors declare no competing interests.

: not applicable.

Document is current

Any future updates will be listed below